“Real‑life cost and cost‑effectiveness for tiotropium 18 μg od monotherapy in moderate and severe COPD patients: a 48‑month survey” (2014) Farmeconomia. Health economics and therapeutic pathways, 15(2), pp. 39–44. doi:10.7175/fe.v15i2.924.